| NCT03267810 | TENS Trial to Prevent Neuropathic Pain in SCI | University of Miami | | - Age ≥ 18 yrs
- Level C1-S5
AIS A, B, C, D- ≤ 4 months
| Ended | 31 | NA | Technology | Pain | | | 14 August 2017 | 30 August 2017 | 1 | |
| NCT03292315 | Once Weekly GLP-1 in Persons With Spinal Cord Injury | James J. Peters Veterans Affairs Medical Center | | - Age 18 - 69 yrs
- Level C1-S5
AIS D- 3 months - 69 years
| Ended | 5 | PHASE4 | Drug | General health | | | 16 October 2018 | 25 September 2017 | 1 | |
| NCT03229031 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury | Eusol Biotech Co., Ltd. | | - Age 18 - 65 yrs
- Level C1-S5
AIS A- ≤ 65 years
| Ended | 160 | PHASE3 | Drug | Standing/walking/mobility | | | 07 March 2018 | 25 July 2017 | 4 | |
| NCT03225625 | Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study | MD Stem Cells | | - Age ≥ 18 yrs
- Level C1-S5
AIS A, B, C, D- ≤ 0 hours
| By invitation | 40 | NA | Biological/cell based | General health | | | 01 July 2017 | 21 July 2017 | 2 | |
| NCT03187795 | Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury | Kessler Foundation | | - Age 18 - 70 yrs
- Level C1-T11
AIS A, B, C, D- ≥ 12 months
| | 62 | PHASE2 | Drug | Bladder health/function | | | 03 April 2019 | 15 June 2017 | 1 | |
| NCT03179475 | Targin® for Chronic Pain Management in Patients With Spinal Cord Injury | University of British Columbia | | - Age 18 - 65 yrs
- Level C1-S5
AIS A, B, C, D- 3 months - 65 years
| Ended | 1 | PHASE4 | Drug | Pain | | | 05 September 2019 | 07 June 2017 | 1 | |
